← ANALYST RATINGS · TIPRANKS
Innate Pharma (IPHA): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $6.67, the highest $9.00, the lowest $4.00. The average is +366.2% from the last price of $1.43.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 → $1.50−25.0% | Hold | +4.9% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 → $1.50−25.0% | Hold | +4.9% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 → $1.50−25.0% | Hold | +4.9% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 → $1.50−25.0% | Hold | +4.9% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 → $1.50−25.0% | Hold | +4.9% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $2.00 → $1.50−25.0% | Hold | +4.9% | Reiterated | 03.10.26on TipRanks 05:05 | — | |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $7.00 | Buy | +389.5% | Reiterated | 01.10.26on TipRanks 10:35 | −2.6%next day −2.6% · 5 days −8.2% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $9.00 | Buy | +529.4% | Reiterated | 17.09.26on TipRanks Sep 18 06:55 | −6.1%next day −0.7% · 5 days −11.8% | ↗ |
| Daina Graybosch★★★★★★★★★★#12254 · hits 39% · avg −7.8% | Leerink Partners | $3.00 → $4.00+33.3% | Buy | +179.7% | Upgrade | 11.08.26on TipRanks 06:20 | −2.8%next day +14.6% · 5 days −3.3% | ↗ |
| Christopher Liu★★★★★★★★★★#2941 · hits 44% · avg +8.9% | Lucid Capital | $8.00 | Buy | +459.4% | Initiated | 23.10.25on TipRanks 07:45 | +4.2%next day −0.4% · 5 days −10.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Innate Pharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $6.67 at a price of $1.63 (+309.0%); now: $6.67 at $1.43 (+366.2%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 4 | 3 | 4 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 25.03.27 (Q4 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.29 (from $-0.29 to $-0.29). Last quarter: $-0.24.
Sales
Next quarter’s sales estimate — $3M (from $3M to $3M). Last quarter: $4M.
Best top-analyst consensus in the sector · Healthcare
About Innate Pharma
- CEO: Jonathan E. Dickinson
- Employees: 163
- 117, Avenue de Luminy, Marseille, PAC, 13009, FR
- www.innate-pharma.com
Innate Pharma S.A. is a biotechnology firm, founded in 1999 and headquartered in Marseille, France, that specializes in the discovery, development, and market introduction of therapeutic antibodies. The company primarily targets oncology indications across France and internationally, with some programs also addressing inflammatory diseases and viral infections. Its clinical-stage pipeline features several key assets: Lacutamab (IPH4102): An anti-KIR3DL2 antibody undergoing Phase II trials for cutaneous T-cell and peripheral T-cell lymphoma, and also for refractory Sézary syndrome. Monalizumab: An immune checkpoint inhibitor currently in Phase III clinical trials for various advanced solid tumors, including colorectal, lung, and head and neck cancers. Avdoralimab (IPH5401): A monoclonal antibody designed to block C5a binding to C5aR1, which is in Phase II development for COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory conditions. IPH5201: A blocking antibody in Phase I trials, focused on the CD39 immunosuppressive pathway. IPH5301: An anti-CD73 antibody developed to enhance anti-tumor immunity by targeting the immunosuppressive adenosine pathway. IPH6101: An NKp46-based NK cell engager being evaluated for the generation of up to two bispecific NK cell engagers. Innate Pharma also maintains an active preclinical pipeline, including IPH43 (an anti-MICA/B antibody drug conjugate), an Anti-Siglec-9 antibody program, IPH65 (a proprietary tetraspecific antibody), IPH25 (a checkpoint inhibitor), and the IPH62 and IPH64 programs. The company has established strategic licensing and collaboration agreements with major industry players such as AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech, alongside a co-development and license agreement with MedImmune Limited.
Data from the stock’s TipRanks forecast page, read 105 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗